Cite
MLA Citation
Greg Hapgood et al.. “A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.” Leukemia & lymphoma, vol. 60, no. 4, 2019, pp. 904–911. http://access.bl.uk/ark:/81055/vdc_100079933386.0x00005c